GlassScriptPhysician profile
Muhammad Ihsan
NPI 1114210309
$5,431.61
in general payments reported to CMS, 2019-2025
27 companies · $799 in 2025
The $799 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $1,814 · 2021: $245 · 2022: $79.51 · 2023: $759 · 2024: $290 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.17 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,899.10 | 2019-2025 | Perclose Prostyle, Diamondback Peripheral, Optis |
| Abiomed | $827.90 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $475.09 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Nuwellis, INC. | $333.27 | 2019-2020 | |
| Boston Scientific Corporation | $287.14 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $195.18 | 2019-2021 | |
| Spectrawave, INC | $189.36 | 2023 | Hypervue Imaging System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.43 | 2019 | |
| Canon Medical Systems USA, INC. | $143.26 | 2023 | Interventional Angiography System |
| Astrazeneca Pharmaceuticals LP | $140.41 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $138.07 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.99 | 2022-2024 | Jardiance |
| Terumo Medical Corporation | $97.47 | 2019-2023 | Metacross Otw, Azur Cx Detachable |
| Medtronic, INC. | $79.72 | 2021-2025 | Corevalve Evolut R |
| Amgen INC. | $74.66 | 2023-2025 | Repatha, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.90 | 2025 | Camzyos |
| Esperion Therapeutics, INC. | $36.81 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $36.39 | 2023-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $27.50 | 2019 | |
| Medtronic Vascular, INC. | $26.78 | 2020 | |
| Lilly USA, LLC | $24.74 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $24.06 | 2022 | |
| Chiesi USA, INC. | $20.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.69 | 2025 | |
| Biotronik INC. | $12.24 | 2021 | |
| Cardiovascular Systems INC. | $11.44 | 2019 | |
| Z-Medica, LLC | $3.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ihsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.